Vladimir Murovec boasts nearly a decade of experience as an EU regulatory and compliance lawyer specialising in the Life Sciences and Healthcare sectors. His expertise spans a wide array of areas including medical devices, in vitro diagnostics, (bio)pharmaceuticals, and digital health technologies.
Clients rely on Vladimir for advice on various regulatory matters, from research and development activities to marketing authorisations, CE-marking procedures, manufacture of products, cross-border distribution, advertising, and product liability risks. Combining extensive in-house secondment experience and a strong academic background, he is recognised as a compliance expert, guiding companies on ethical engagements with healthcare professionals, organisations, and patients' groups. Notably, Vladimir represents both EU and non-EU businesses in dealings with European regulators, national authorities, and industry associations.
With a keen focus on quality management systems (QMS) and good practices (GxP), Vladimir assists in global supply chain decision-making and the implementation of internal procedures.
Vladimir is a sought-after speaker at international industry events, on regulatory and compliance topics in the Life Sciences space. He has taught EU life sciences regulations in business schools and serves as an associate editor of the European Health and Pharmaceutical Law Review (EHPL). He is a member of the international regulatory affairs professional society (RAPS).
Vladimir is recognised by Who's Who Legal (Life Sciences) for his expertise in Regulatory matters. He is listed as a ‘Rising Star’ by The Legal 500 for his work in Healthcare and Life Sciences and noted as a go-to lawyer in EU Regulatory: Pharma, Medical Device and Biotech.
Vladimir Murovec is well regarded in the market for his top-tier regulatory practice advising clients in the pharmaceuticals, medical devices and healthcare industries.
Who's Who Legal, 2024
Vladimir combines unique expertise in both pharma as well as medical device regulatory matters with a broad knowledge of most other legal domains that are of interest to our industry.
The Legal 500, 2022
Insights
New EU AI Act is poised to shape the future for life sciences in Europe
Navigating Belgium's life sciences terrain: a strategic overview
From hemp to highs: an overview of cannabis and CBD legislation across Europe
EU's 'flexible' pharma reforms likely to require fine-tuning to address uncertainties
EU to reform rules for drug-device combinations, product information and pharmacovigilance
EU pharmaceutical reforms to overhaul marketing and manufacturing rules
New year brings healthcare professional interaction rule update in Belgium
Products without an intended medical purpose: EU clarifies conditions
New Belgian medical devices and in vitro diagnostics legislation comes into force
The transposition of EU medtech regulations is progressing in Belgium – with repercussions for all medtech businesses active there .